TY - JOUR
T1 - Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
AU - Mazharuddin, Anam A.
AU - Whyte, Andrew T.
AU - Gombos, Dan S.
AU - Patel, Nimisha
AU - Razmandi, Azadeh
AU - Chaudhry, Amina L.
AU - Al-Zubidi, Nagham S.
N1 - Publisher Copyright:
© 2022, Innovative Healthcare Institute. All rights reserved.
PY - 2022/11
Y1 - 2022/11
N2 - Introduction: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and clinical outcomes of ocular irAEs. Methods: In this retrospective, observational case series, we reviewed the medical records of 1280 patients at a large US tertiary cancer center between 2010 and 2020. Results: We identified 130 patients who presented with ocular irAEs (10%) with 69 males (53%) and 61 females (47%). The mean time to toxicity was 6.1 months. Adverse events include corneal toxicity (31%), neuro-ophthalmic (14%), uveitis and scleritis (13%), retinopathy (13%), periocular disorders (11%), and others. IrAEs occurred most frequently with nivolumab (26%). Most ocular irAEs were treated with topical therapy. Advanced cases required systemic corticosteroids and even cessation of ICIs. Conclusion: Our cohort is a large case series highlighting the increased potential of ocular toxicity associated with ICIs. Prompt recognition and management of ocular irAEs can minimize their effect.
AB - Introduction: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and clinical outcomes of ocular irAEs. Methods: In this retrospective, observational case series, we reviewed the medical records of 1280 patients at a large US tertiary cancer center between 2010 and 2020. Results: We identified 130 patients who presented with ocular irAEs (10%) with 69 males (53%) and 61 females (47%). The mean time to toxicity was 6.1 months. Adverse events include corneal toxicity (31%), neuro-ophthalmic (14%), uveitis and scleritis (13%), retinopathy (13%), periocular disorders (11%), and others. IrAEs occurred most frequently with nivolumab (26%). Most ocular irAEs were treated with topical therapy. Advanced cases required systemic corticosteroids and even cessation of ICIs. Conclusion: Our cohort is a large case series highlighting the increased potential of ocular toxicity associated with ICIs. Prompt recognition and management of ocular irAEs can minimize their effect.
KW - immune checkpoint inhibitors
KW - immunotherapy side effects
KW - nivolumab
KW - ocular immune-related adverse events
KW - ocular toxicity
UR - http://www.scopus.com/inward/record.url?scp=85162923175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162923175&partnerID=8YFLogxK
U2 - 10.36401/JIPO-22-14
DO - 10.36401/JIPO-22-14
M3 - Article
C2 - 36483585
AN - SCOPUS:85162923175
SN - 2666-2345
VL - 5
SP - 98
EP - 104
JO - Journal of Immunotherapy and Precision Oncology
JF - Journal of Immunotherapy and Precision Oncology
IS - 4
ER -